International Trade Bulletin - Volume 1, Issue 13
Client Alert | 1 min read | 09.06.06
Inside this issue:
- EUROPE IN THE SPOTLIGHT
- GMOs: The EU – U.S. controversy over the spread of unauthorized genetically modified rice fuels the already infected cross-Atlantic GMO debate
- EU Anti-Dumping: European Commission publicly acknowledges that it has started a comprehensive review of the way that the EU will apply anti-dumping measures in the future
- CUSTOMS CLASSIFICATION: After Doha: Practical Approaches for Cutting the Costs of Trade
- C-TPAT: C-TPAT Develops New Minimum Security Criteria for Foreign Manufacturers effective August 29, 2006
- CHINA: Bureau of Industry and Security Holds Regional Meetings with the Public to Explain New Proposed Export Control Rules for China
- MARKET ACCESS: With the collapse of the World Trade Organization's Doha Round and no clear timeline for its resurrection, member countries are expected to focus renewed attention on bilateral and regional free trade agreements (FTAs)
- SANCTIONS: The U.S. considers sanctions options on Iran
- PRIVACY: Commission Announces New Initiatives on EU-U.S. Passenger Data Transfer: More of the Same or Expanded Access to Such Data?
- IRAN: Focus on Iran – Singapore Airlines Joint Venture Sanctioned by OFAC
- JAPAN: Japanese Executives Arrested for Violation of Japan's Export Control Laws
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
Client Alert | 2 min read | 09.11.26
New ISOO Guidance Directs Federal Agencies to Provide More CUI Guidance to Contractors
